Conducting clinical research in Africa can be fraught with risk. From overcoming basic infrastructure obstacles and finding reliable talent, to addressing personal safety issues for your team, these projects require an entirely different level of management and oversight.
But Africa also offers tremendous opportunities for biopharmaceutical companies interested in doing research into a wide range of prevalent and neglected diseases, including Malaria, HIV, Tuberculosis and sickle cell anemia. Over the last eight years, global funding for neglected diseases has grown substantially, reaching $3.165 billion in 2012, and much of this research is being done in Africa.
Biopharma companies who want to participate in these philanthropic endeavors need to overcome their fears about working...